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Introduction: The role of the progesterone receptor (PR) in breast cancer remains a major clinical challenge.
Although PR induces mammary tumor growth, its presence in breast tumors is a marker of good prognosis. We
investigated coordinated PR rapid and nonclassical transcriptional effects governing breast cancer growth and
endocrine therapy resistance.
Methods: We used breast cancer cell lines expressing wild-type and mutant PRs, cells sensitive and resistant to
endocrine therapy, a variety of molecular and cellular biology approaches, in vitro proliferation studies and preclinical
models to explore PR regulation of cyclin D1 expression, tumor growth, and response to endocrine therapy. We
investigated the clinical significance of activator protein 1 (AP-1) and PR interaction in a cohort of 99 PR-positive
breast tumors by an immunofluorescence protocol we developed. The prognostic value of AP-1/PR nuclear
colocalization in overall survival (OS) was evaluated using Kaplan-Meier method, and Cox model was used to explore
said colocalization as an independent prognostic factor for OS.
Results: We demonstrated that at the cyclin D1 promoter and through coordinated rapid and transcriptional effects,
progestin induces the assembly of a transcriptional complex among AP-1, Stat3, PR, and ErbB-2 which functions as an
enhanceosome to drive breast cancer growth. Our studies in a cohort of human breast tumors identified PR and AP-1
nuclear interaction as a marker of good prognosis and better OS in patients treated with tamoxifen (Tam), an
anti-estrogen receptor therapy. Rationale for this finding was provided by our demonstration that Tam inhibits
rapid and genomic PR effects, rendering breast cancer cells sensitive to its antiproliferative effects.
Conclusions: We here provided novel insight into the paradox of PR action as well as new tools to identify the
subgroup of ER+/PR + patients unlikely to respond to ER-targeted therapies.* Correspondence: patriciaelizalde@ibyme.conicet.gov.ar
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The progesterone receptor (PR) is a key hormonal player
in the breast cancer scenario [1]. However, understanding
the molecular mechanisms through which PR controls
breast cancer growth and response to endocrine treat-
ments remains a major clinical challenge. In its classical
mechanism, PR acts as a ligand-induced transcription fac-
tor (TF) interacting with specific progesterone response
elements (PREs) in the promoter of target genes. In
addition, rapid or nongenomic PR effects in breast cancer
have been described in several works, including ours,
demonstrating [2] PR ability to activate c-Src, p42/p44
mitogen-activated protein kinases (MAPKs) [3-5], phos-
phatidylinositol 3-kinase (PI-3 K)/Akt [5], and Jaks/signal
transducer and activator of transcription 3 (Stat3) [6,7]
pathways, which in turn mediate multiple aspects of PR
function [1,8]. We also revealed that progestin induces the
rapid phosphorylation of the ErbB-2 receptor tyrosine kin-
ase [9], whose involvement in mammary tumorigenesis
has long been known [10], and ErbB-2 nuclear transloca-
tion in breast cancer [9]. Intriguingly, progestin regulates
the expression of an important number of genes which
lack canonical PREs in their promoters, including key reg-
ulators of cell cycle progression, such as cyclin D1,
p21CIP1 and p27KIP1 [11-13]. This may occur via a non-
classical PR transcriptional mechanism through PR tether-
ing to other TFs in the promoter of target genes. This
mechanism raises the exciting question of whether PR
rapid stimulation of signaling pathways induces the phos-
phorylation of TFs that in turn participate in nonclassical
PR transcriptional tethering mechanisms. Cyclin D1 is an
ideal gene to answer this query. We and others have long
shown that progestin induces cyclin D1 gene expression
in breast cancer [8,9,11]. On the other hand, several works
demonstrated that progestin rapid activation of p42/
p44MAPKs mediates PR regulation of Cyclin D1 expres-
sion in mammary tumor cells [8,11]. The complex cyclin
D1 promoter contains response elements for a large num-
ber of TFs, among them an activator protein 1 (AP-1) site
[14]. AP-1 factor is a dimer composed by Jun and Fos
family members that recognizes a cis-tetradecanoyl phor-
bol acetate-responsive element (TRE) [15]. Progestin up-
regulation of c-Fos and c-Jun expression in breast cancer
has long been found [16]. The transcriptional activity of
AP-1 is modulated by signaling cascades, including c-Jun
N-terminal (JNK) and p42/p44MAPKs, which upon acti-
vation by growth factors and serum induce Jun and Fos
protein phosphorylation [17-19]. In addition, AP-1 in-
volvement in breast cancer growth and expression of
AP-1 members in human breast cancer have also been
reported [20-22].
Here we put together the pieces of the puzzle linking PR
rapid activation of p42/p44MAPKs to AP-1 transcriptional
activity and to the assembly of PR transcriptional complexesgoverning cyclin D1 expression and breast cancer growth.
We also identified that in human breast tumors, nuclear
colocalization of PR and activated c-Jun is a novel marker of
better overall survival (OS) in patients receiving anti-
estrogen receptor (ER) therapy with tamoxifen (Tam) and
revealed a new mechanism underlying Tam resistance.
Methods
Animals and tumors
Experiments were carried out with female BALB/c mice
raised at the Instituto de Biología y Medicina Experimental
(IBYME). Animal studies were conducted as described
[9,23], in accordance with the standards of animal care
as outlined in the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the IBYME
Animal Research Committee.
Patients and tissue microarrays (TMAs)
The Review Board on Human Research of Universidad
de La Frontera (UF) reviewed and approved the collec-
tion of tumor specimens, our survey data, and all clinical
and pathological information as well as the retrospective
biomarker analyses on anonymized specimens from the
Temuco Hospital archival cohort. We selected 99 PR +
paraffin-embedded tissue samples from a cohort of 273
consecutively archived invasive breast carcinomas from
the files of the Histopathology Department of Temuco
Hospital, Chile, from 1998 to 2006 [24]. Follow-up data
were available for up to 13 years with a median follow-up
time of 53 months. All retrospectively selected patients
were treated with surgery, and 85 received tamoxifen after
surgery. Informed written consents were obtained from all
patients before inclusion. Pre-treatment patient staging
was classified according to the American Joint Committee
on Cancer (AJCC) system [25] through the Elston and
Ellis histological grading system [26]. TMAs were con-
structed at the UF TMA Core Facility. In brief, H&E
sections of all tumors were re-evaluated by a patholo-
gist (PG) for suitability for TMA construction. Repre-
sentative areas of tumor sections for each case were
selected and circled to match the blocks for the tissue
microarray. Blocks matching the circled slides were
then retrieved to prepare the recipient block for the
microarray. To assure the representation of selected
cores, two areas of tumor sections per case were deter-
mined for assembly of the recipient blocks. Each target
area on the selected blocks was punched to form a 2-mm-
diameter tissue core and was placed consecutively on ap-
proximately 3 × 2 cm recipient blocks using a tissue
microarrayer (Beecher Instrument, Silver Spring, MD,
USA). To assure the specificity of our results, C4HD tu-
mors growing in the presence and absence of MPA were
included in the TMAs as positive and negative controls,
respectively. Tissue microarrays were then cut to 5 μm
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first and last slides were stained for H&E.
Antibodies and reagents
Antibodies and reagents used are detailed under Supple-
mental methods (see Additional file 1).
Cells, treatments and proliferation assays
C4HD epithelial cells from the model of mammary car-
cinogenesis induced by MPA in mice display high levels
of ER and PR, lack glucocorticoid and androgen receptor
and overexpress ErbB-2 [2]. T47D and BT474 breast
cancer cells were obtained from the American Type Cul-
ture Collection. T47D-Y cells were a gift from K. Horwitz
(University of Colorado Health Sciences Center, Denver,
CO, USA). BT474-HR6 clone, selected for its resistance to
the ErbB-2 antibody trastuzumab, was already described
[27] and was a gift from C. Arteaga (Vanderbilt University,
Nashville, TN, USA). Selection of another trastuzumab-
resistant clone, BT474-HR, was done following the previ-
ously described protocol [27]. Primary cultures of epithe-
lial cells from C4HD tumors were performed as described
[9]. T47D cell variants were cultured as we previously de-
scribed (6) BT474 cells were cultured in RPMI 1640 [28]
and both BT474-HR and HR6 clones in IMEM both sup-
plemented with 10% fetal calf serum (FCS). All cell types
were starved in 0.1% charcolized FCS (ChFCS) for 48 h
before stimulation with MPA or E2 as detailed under
Results or were pretreated with RU486 or Tam for 90
minutes before MPA or E2 stimulation. In experiments
assessing the effects of mutant c-Jun (TAM-67), c-Fos
(A-Fos) or ErbB-2 (hErbB-2ΔNLS) cells were transfected
as we already described with the corresponding plasmid
or empty plasmid for 24 h before MPA treatment [9]. To
study cell proliferation we used [3H]-thymidine incorpor-
ation as a measure of DNA synthesis. We already demon-
strated that [3H]-thymidine uptake correlates with the
number of cells/well in our C4HD model system [2],
which is a direct measure of cell proliferation. In addition,
cell cycle distribution was analyzed by flow cytometry as
we described [9].
Western blots
SDS-PAGE and immunoblots were performed as we previ-
ously described [9]. The NE-PER Nuclear and Cytoplasmic
Extraction Reagents technique (Pierce Biotechnology,
Rockford, IL, USA) was performed as per the manufac-
turer’s instructions. Experiments in which phosphoryl-
ation levels of c-Jun, c-Fos, c-Src and p42/p44 MAPKs
were explored were repeated three to five times. Experi-
ments assessing cyclin D1, ErbB-2, PR and ERα protein
levels were also repeated three to five times. Signal inten-
sities of phospho-proteins were analyzed by densitometry
and normalized to total protein bands. Similarly, signalintensities of cyclin D1, ErbB-2, PR and ERα bands were
normalized to actin or β-tubulin bands. Data analysis
showed a significant increase in protein phosphoryl-
ation by MPA or Tam when indicated, in comparison
with untreated cells and a significant inhibition of
MPA-induced phosphorylation by RU486, UO126 or
Tam as described under Results (P <0.001). A similar
data analysis showed that compared to control cells, the
increase in cyclin D1 levels by MPA treatment was signifi-
cant, as was the inhibition of MPA effects by TAM-67, A-
Fos, ErbB-2ΔNLS, c-Jun and c-Fos siRNAs or Tam when
indicated), and that expression levels of PR-A and –B in
BT474-HR and HR6 clones were significantly lower as
compared to those in BT474 cells (P <0.001). Differences
between groups were analyzed by unpaired two-tailed Stu-
dent’s t test.
Plasmids and transient transfections
The luciferase reporter plasmid downstream of the cyc-
lin D1 human promoter region (−1745 cyclin D1-Luc), a
construct truncated at position −963 with a point muta-
tion in the TRE site, and the empty vector pA3 Luc were
provided by R. Pestell (Northwestern University Medical
School, Chicago, IL, USA). The luciferase reporter plas-
mid containing three copies of the TRE binding site
(AP-1/TRE:Luc) was a gift from S. Cook (Cambridge,
UK). The Renilla luciferase expression plasmid RL-CMV
and the MMTV-Luc vector were obtained from Pro-
mega (Madison, WI, USA). Dominant negative c-Jun ex-
pression vector, TAM-67 [29] was provided by M. Shipp
(Dana-Farber Cancer Institute, Boston, MA, USA) via
G. Rabinovich (IBYME, Buenos Aires, Argentina). The
dominant negative c-Fos expression vector, A-Fos [30],
was a gift from C. Vinson (NCI, NIH, Bethesda, MD,
USA). The GFP-tagged human ErbB-2 mutant which
lacks the putative nuclear localization signal sequence
(hErbB-2ΔNLS), was provided by M.C. Hung (The
University of Texas M.D. Anderson Cancer Center,
Houston, TX, USA) [31]. Plasmids encoding the hu-
man wild-type hPR-B and the mutant C587A-PR-B,
which lacks the ability to bind to DNA [32], were pro-
vided by K. Horwitz. The mutant PR-BmPro [4] was a
gift from D. Edwards (Baylor College of Medicine,
Houston, TX, USA). Tranfections of T47D-Y cells with
C587A-PR-B and PR-BmPro mutants were conducted
as we previously described using vector concentrations
which resulted in mutant PRs expression levels comparable
to those present in T47D cells [5]. In experiments assessing
MPA capacity to induce the transcriptional activation of
AP-1, C4HD and T47D cells were transiently transfected
for 24 h with 1 μg of AP-1/TRE:Luc reporter, -1745 cyclin
D1-Luc reporter plasmid, or the truncated −963 construct
and 10 ng of RL-CMV used to correct variations in trans-
fection efficiency. As a control, cells were transfected with
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were cotransfected with 300 ng of TAM-67 or A-Fos when
indicated. The total amount of transfected DNA was stan-
dardized by adding empty vectors. Cells were then starved
in serum-free medium for 24 h and treated with MPA dur-
ing 18 h, or were left untreated. Fugene HD transfection
reagent technique (Roche Diagnostics Corporation,
Indianapolis, IN, USA) was performed as described [9].
Transfected cells were lysed and luciferase assays were
carried out using the Dual-Luciferase Reporter Assay Sys-
tem (Promega) in accordance with the manufacturer’s in-
structions. Transfection efficiencies were evaluated using
the pEGFP-N1 vector (BD Biosciences Clontech, Palo
Alto, CA, USA) as we already described [9]. Triplicate
samples were analyzed for each datum point. Differences
between experimental groups were analyzed by
ANOVA followed by Tukey’s test between groups. siR-
NAs sequences are detailed under Supplemental
methods (see Additional file 1). Transfection of siR-
NAs was performed by using the DharmaFECT transfec-
tion reagent (Dharmacon, Lafayatte, CO, USA) for two
days following the manufacturer’s instructions.
Immunofluorescence and confocal microscopy in cell
cultures
Techniques were performed as we already described [9].
Cells were analyzed using a laser microscopy system
(Nikon, Tokyo, Japan) [9]. We performed quantitative
analysis of confocal immunofluorescence images with
Image J [33] to evaluate the percentages of c-Jun and
c-Fos localized in the nucleus and cytosol. The nuclear
compartment was defined according to the DAPI im-
ages. We obtained an integrated intensity value for
total c-Jun (c-JunT) or c-Fos (c-FosT) and for nuclear
c-Jun (c-JunN) or c-Fos (c-FosN) for each selected cell.
Green channel background (median) was subtracted in all
cases. To compute the distribution of c-Jun and c-Fos, we
calculated the ratio of the integrated intensities of c-JunN/
c-JunT or of c-FosN/c-FosT for 50 to 80 cells and ob-
tained an average value.
In situ proximity ligation assay (PLA)
PLA was performed using the Duolink kit (Olink Biosci-
ences, Uppsala, Sweden). Rabbit PLA PLUS and mouse
PLA MINUS probes were then incubated at 37°C for 1 h
followed by ligation, rolling circle amplification and de-
tection, according to the manufacturer’s protocol.
Bioinformatics inference of transcription factor binding sites
Transcription factors motif sequence analysis was
performed using MAST [34] and FIMO [35] tools on
the −3015 to +1570 region of the human Cyclin D1 gene
(GenBank AC Z29078), which contains the cyclin D1
promoter. The AP-1 motif (MA0099.2) was downloadedfrom JASPAR [36] and the STAT3 motif (M00225) from
TRANSFAC [37]. ErbB-2 binding motif (HAS) has already
been described [38]. Our previous bioinformatics analysis
did not identify HAS sites in the −3015 to +1570 cyclin D1
region [9]. PRE motif identified by Clarke and Graham
[39], using MEME-chromatin immunoprecipitation (ChIP)
[40], from peaks associated with top regulated genes in
T47D cells stimulated with progestin, was obtained from
the authors. MAST identifies putative binding site posi-
tions and calculates a position P-value for every motif
match, being the position P-value the probability of at least
a single random subsequence of the length of the motif,
scoring as well as the observed match. FIMO was used to
double-check the identified binding positions and to obtain
a q-value for every motif occurrence, which is defined as
the false discovery rate if the occurrence is accepted as
significant.
ChIP and sequential ChIP assays and real-time quantitative
PCR (qPCR)
ChIP and sequential ChIP were performed as we already
described [9]. Chromatin was sonicated to an average of
about 200 bp. Primers used for qPCR are listed in the
Supplemental methods (see Additional file 1).
RNA preparation and real-time quantitative RT-PCR
RNA was obtained and cyclin D1 mRNA levels were
detected as we already described [9]. Primers used for
qPCR are listed in the Supplemental methods (see
Additional file 1).
Preclinical models
C4HD cells were transiently transfected with the indi-
cated expression vectors and 106 cells from each experi-
mental group were inoculated subcutaneously (s.c.) into
animals treated with a 40-mg MPA depot in the flank
opposite to the cell inoculum. Tumor volume, growth
rate and growth delay were determined as previously de-
scribed [9]. Comparison of tumor volumes between the
different groups was done by analysis of variance
followed by Tukey’s test among groups. Linear regres-
sion analysis was performed on tumor growth curves,
and the slopes were compared using analysis of variance
followed by a parallelism test to evaluate the statistical
significance of differences.
Immunofluorescence detection of PR and p-c-Jun in
tumor samples
Antigen retrieval was performed by immersing the sec-
tions in 10 mM sodium citrate buffer pH 6 and micro-
waving at high power for four minutes. Slides were
blocked in Modified Hank’s Buffer (MHB) with 5% bo-
vine serum albumin for 30 minutes and were incubated
overnight at 4°C with the following primary antibodies:
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Cruz, CA, USA) and monoclonal mouse anti-human Pro-
gesterone Receptor, clone PgR 1294 (DAKO, Glostrup,
Denmark). Slides were then incubated with the correspond-
ing Alexa 488-conjugated antibody (1:1000, Molecular
Probes, Eugene, OR, USA). Reduction of the autofluor-
escent background was performed by incubation with
Sudan Black B 0.1% (Sigma-Aldrich, St. Louis, MO,
USA). Nuclei were stained with propidium iodide or
DAPI (4′,6-diamidino-2-phenylindole). Negative controls
were carried out with MHB instead of primary antibodies.
C4HD tumors from the model of mammary tumors in-
duced by progestins were also used as controls [9]. Slides
were independently scored by two pathologists (PG and
EM). Score discrepancies were re-evaluated and recon-
ciled on a two-headed microscope. A third pathologist
(JCR) participated in IF staining and evaluation. PR ex-
pression levels detected by IF were scored in accordance
to the “Allred score” routinely used for PR detection by
IHC in the clinic [41]. Nuclear p-c-Jun levels detected by
IF were also scored by the Allred system, considering both
the percentage of positive cells and staining intensity. In
brief, a score was assigned according to the proportion of
stained tumor cells (0 = none; 1 <1/100; 2 = 1/100 to <1/
10; 3 = 1/10 to <1/3; 4 = 1/3 to 2/3; 5 = >2/3). Intensity of
staining was assigned a score of 0 (none), 1 (weak), 2 (inter-
mediate) and 3 (strong). Percentage and intensity scores
were added to obtain a total score that ranged from 0 to 8.
Statistics
Analyses were performed using STATA version 11 software
(Stata Corp., College Station, TX, USA). Correlations be-
tween categorical variables were performed using the χ2-test
or Fisher’s exact test. Cumulative overall survival probabil-
ities were calculated according to the Kaplan-Meier method,
and statistical significance was analyzed by log-rank test.
Multivariate analysis was performed using the Cox multiple
hazards model. Adjustment for significant confounders was
done to avoid increased bias and variability or unreliable
confidence interval coverage [42]. Variables included in the
Cox model were those which resulted in statistically signifi-
cance (P <0.05) in the log rank test (lymph node metastasis,
distant metastasis, ER and clinical stage). The remaining var-
iables were excluded from our analysis (age, tumor size and
tumor grade). All tests of statistical significance were two-
sided. P-values <0.05 were regarded as statistically signifi-
cant. Guidelines for reporting tumor markers (REMARK)
were used as outlined (see Additional file 1: Table S1).
Results
MPA induces the rapid phosphorylation of c-Jun and c-Fos
and AP-1 transcriptional activation via p42/p44 MAPKs
We first explored the ability of the synthetic progestin
medroxyprogesterone acetate (MPA) to phosphorylatec-Jun and c-Fos. We used human breast cancer cell
lines and C4HD epithelial cells from the model of
mammary carcinogenesis induced by MPA in mice.
C4HD cells display high levels of ER and PR and over-
express ErbB-2 [9]. c-Jun phosphorylation was studied
using an antibody which recognizes phospho Ser 63/73.
c-Fos phosphorylation was first explored by the pres-
ence of the upper band in the Western blots revealed
with total c-Fos antibodies [18]. MPA treatment of
C4HD and T47D human breast cancer cells resulted
in rapid phosphorylation of c-Jun and c-Fos, which
was abolished by pre-incubation with the antiprogestin
RU486 or by knockdown of PR expression with PR
small interfering RNAs (siRNAs) (Figure 1A, B and
Additional file 1: Figure 1A). We found no effects of
MPA in the PR-null T47D-Y cells, confirming the in-
volvement of the classical PR (Figure 1B). Transient
transfection of T47D-Y cells with a wild-type PR-B ex-
pression vector (T47D-Y-PR-B), but not with a PR-A
vector (T47D-Y-PR-A), restored MPA effects (Figure 1B).
Blockade of MPA-induced p42/p44 MAPKs activation
with U0126 for the first time revealed their involvement
in progestin-induced phosphorylation of c-Jun and c-Fos
(Figure 1C and Additional file 1: Figure 1B). Transfection
of T47D-Y cells with a mutant PR-BmPro unable to
activate p42/p44 MAPKs ([4] and Additional file 1:
Figure 1C) abolished MPA effects, further demon-
strating that progestin rapid action mediates c-Jun
and c-Fos phosphorylation (Figure 1D). On the other
hand, transfection of T47D-Y cells with a transcrip-
tionally crippled PR-B (C587A) [32], which retains
the capacity to induce p42/p44 MAPKs activation
[4,5], restored MPA effects (Figure 1D). As we previ-
ously showed [5], levels of PR-B expression in cells
transfected with PR-BmPro and C587A-PR mutants
were comparable to those in T47D cells (Figure 1D). Simi-
lar results of MPA regulation of c-Fos phosphorylation
were observed using an antibody which recognizes phos-
phorylated c-Fos (Additional file 1: Figure 1D to F). Im-
portantly, we have previously shown that RU486 did not
modify basal p42/p44 MAPKs activation state in C4HD or
T47D-Y-PR-B cells [5] and here we found neither RU486
effects in T47D cells (not shown).
MPA induces PR and AP-1 nuclear colocalization
Quantification of immunofluorescence staining in the
absence of MPA treatment showed that the majority of
c-Jun (69 ± 1%) localizes in the nuclear compartment of
T47D cells with some staining observed in the cyto-
plasm (31 ± 1%) (Figure 2A). After MPA stimulation,
only nuclear c-Jun was observed (Figure 2A). Abrogation
of MPA-induced c-Jun phosphorylation with U0126
inhibited the massive nuclear translocation of c-Jun
(Figure 2A), indicating that phosphorylation is involved in
Figure 1 MPA induces c-Jun and c-Fos phosphorylation and AP-1 activation via p42/p44 MAPKs. (A) to (D) Cells were pretreated with
RU486 or U0126, transfected with PR siRNAs or PR expression vectors and were then treated with MPA. Western blots (WB) were performed with
phospho (p)-c-Jun and pp42/44MAPKs antibodies and filters were re-probed with the respective total antibody, or with a c-Fos antibody and
re-probed with an actin antibody. Experiments in A to D were repeated five times with similar results. Signal intensities of phospho-proteins
were analyzed by densitometry and normalized to total protein bands. Data analysis showed a significant increase in protein phosphorylation by
MPA in comparison with untreated cells and a significant inhibition of MPA-induced phosphorylation by RU486 or UO126 (P <0.001). See
also Additional file 1: Figure 1. MAPKs, Mitogen-activated protein kinases; MPA, Medroxyprogesterone acetate; PR, Progesterone receptor.
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nuclear colocalization of c-Jun and PR, as shown by the
yellow foci in the merged images (Figure 2A). Cells
treated with U0126 showed no nuclear colocalization
of c-Jun and PR, evidencing that c-Jun phosphorylation
is mandatory for its nuclear interaction with PR. Our quan-
titative immunofluorescence analysis revealed both nuclear
(30 ± 2%) and cytoplasmic (70 ± 2%) c-Fos in untreatedcells where MPA stimulation resulted in significant c-Fos
migration to the nucleus, abolished by U0126 (Figure 2A).
MPA also causes nuclear colocalization of c-Fos with PR,
which was abrogated by U0126 (Figure 2A). Moreover,
subcellular fractionation studies showed that MPA sig-
nificantly increased nuclear c-Jun and c-Fos presence
and phosphorylation levels (Additional file 1: Figure 2). To
further demonstrate the nuclear association of c-Jun and
Figure 2 MPA induces c-Jun, c-Fos and PR nuclear colocalization and physical association. (A) PR, c-Jun and c-Fos were localized by IF and
confocal microscopy. Merged images show MPA-induced c-Jun/PR or c-Fos/PR nuclear colocalization, evidenced by the yellow foci. Boxed areas
are shown in detail in the right insets. Nuclei were stained with DAPI (blue). (B) PR/c-Jun and PR/-c-Fos nuclear interactions were detected by in
situ PLA. The detected dimers are shown by the fluorescent rolling circle products (red). Nuclei were stained with DAPI (blue). The experiments
shown were repeated three times with similar results. See also Additional file 1: Figure 2. MPA, Medroxyprogesterone acetate; PLA, Proximity
ligation assay; PR, Progesterone receptor.
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which showed PR/c-Jun and PR/c-Fos interaction only in
cells treated with MPA (Figure 2B).
MPA modulates cyclin D1 expression via AP-1
We chose Cyclin D1 as a model gene to explore AP-1
involvement in nonclassical PR transcriptional mecha-
nisms. The complex cyclin D1 proximal promoter con-
tains an AP-1 response element (TRE), mapped in
humans at position −954 [14]. We investigated whether
MPA regulates the transcriptional activity of cyclin D1
promoter via induction of AP-1 binding to its response
element. C4HD and T47D cells were transiently trans-
fected with a 1,745-bp human cyclin D1 promoter lucifer-
ase construct containing the −954 TRE. MPA significantly
increased cyclin D1 promoter activity, which was abro-
gated by RU486 (Figure 3A). Consistent with our findings
that MPA induces c-Jun and c-Fos phosphorylation and
consequent AP-1 transcriptional activity via p42/p44
MAPKs, pretreatment of cells with U0126 abolished MPA
effects (Figure 3A). These results are in accordance with
previous findings demonstrating that progestin induction
of cyclin D1 expression at mRNA level requires PRactivation of p42/p22 MAPKs [43]. We did not find
significant effects of either RU486 or U0126 on basal
transcriptional activity of the cyclin D1 promoter in
our cell models (Figure 3A illustrates results in C4HD
cells). Co-transfection with the dominant negative
(DN) forms of c-Jun (TAM-67) [29] and c-Fos (A-Fos)
[30], previously shown to inhibit AP-1 activity, inhib-
ited MPA effects (Figure 3A), indicating that MPA
regulation of cyclin D1 promoter occurs directly via
induction of c-Jun and c-Fos binding to the TRE. Muta-
tion of the AP-1 site (−963 mut AP-1), which abolishes
AP-1 binding [14], inhibited MPA effects (Figure 3A). No
effects of TAM-67 or A-Fos were found on progestin
activation of a control PRE-Luc reporter (not shown). In
addition, transfection of C4HD and T47D cells with
TAM-67 and A-Fos or knockdown of c-Jun and c-Fos ex-
pression using siRNAs (Additional file 1: Figure 1G, H) in
C4HD cells abrogated MPA-induced cyclin D1 protein ex-
pression (Figure 3B,C). MPA induced a 2.5-fold increase
of cyclin D1 mRNA expression in C4HD cells which was
suppressed by silencing the expression of c-Jun or c-Fos
(Figure 3D), confirming both proteins involvement in
MPA transcriptional regulation of cyclin D1.
Figure 3 MPA modulates cyclin D1 expression via AP-1. (A) Cells were transfected with a cyclin D1 promoter luciferase construct containing
the −954 TRE and with a construct with a point mutation in the TRE (−963 mut AP-1). When indicated, cells were co-transfected with TAM-67 or
A-Fos and were then treated with MPA or pretreated with RU or U0 before MPA stimulation. As control of PR transcriptional activity cells were
transfected with a PRE-Luc plasmid and stimulated with MPA. Results are presented as fold induction of luciferase activity with respect to cells
untreated with MPA. Data represent the mean of three independent experiments for each cell type ± SEM. For b vs. a, and c vs. b: P <0.001.
pA3 Luc, empty vector. MPA induces cyclin D1 expression at protein and mRNA levels via AP-1. Cells were transfected with TAM-67 and A-Fos
vectors (B) and with c-Jun and c-Fos siRNAs (C) and then treated with MPA. Cyclin D1 protein expression was analyzed by WB. (D) Cyclin D1 mRNA
expression levels were determined by RT-qPCR. The fold change of mRNA levels upon MPA treatment was calculated by normalizing the absolute
levels of cyclin D1 mRNA to GAPDH levels, which was used as internal control, and setting the value of untreated cells as 1. Experiments shown
were repeated three times with similar results. MPA, Medroxyprogesterone acetate.
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promoter
To assess whether PR tethers to AP-1 in the proximal
cyclin D1 promoter, we performed ChIP assays. First, we
conducted a bioinformatics analysis to investigate thepresence of PREs, previously identified in T47D cells
[39], using MAST [34] and FIMO [35] with default
parameters. This analysis on the −3015 to +1570 region
of the human Cyclin D1 gene, containing the cyclin D1
promoter, did not detect significant PREs. In order to
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this region, we also used the weak matches option (−w) of
MAST and FIMO tools. Using this option, we only identi-
fied a weak/absent putative PRE (position P-value =
0.00031, q-value = 0.742) located 114 bp downstream from
the TRE we are studying here. These studies indicate that
PR recruitment to the region of the cyclin D1 promoter
under study would not occur via direct binding to its
response elements in the chromatin. Our findings in
C4HD cells using primers flanking the −948 mouse
TRE site showed a significant MPA-induced binding of
c-Jun, c-Fos, and PR to the cyclin D1 promoter after
30 minutes of treatment (Figure 4A). Similar results
were found in T47D cells (Figure 4A). MPA-induced
phosphorylation of c-Fos and c-Jun via p42/p44 MAPKs is
mandatory for both proteins loading at the TRE site of the
cyclin D1 promoter, as shown by the lack of recruitment
of said proteins in T47D cells pretreated with U0126
(Figure 4A). As expected for a PR tethering transcrip-
tional mechanism, in the absence of AP-1 binding to
the cyclin D1 promoter in cells treated with U0126, PR
is not recruited to this site upon MPA stimulation
(Figure 4A). Our results using a sequential ChIP showed
that c-Jun, c-Fos and PR co-occupy cyclin D1 promoter
after 30 minutes stimulation with MPA (Figure 4B). To
further demonstrate that a functional transcriptional com-
plex between AP-1 and PR is involved in MPA-induced
cyclin D1 promoter activation and protein expression, we
used the C587A-PR mutant. Previous findings [32], as well
as our own work [9], showed that C587A-PR is unable to
tether to other transcription factors. Consistent with our
results showing that MPA induces the phosphorylation of
c-Jun and c-Fos in T47D-Y-C587A-PR cells (Figure 1D),
we observed the recruitment of both proteins to the TRE
site of cyclin D1 promoter; however, C587A-PR was not
loaded at this promoter (Figure 4C). In the absence of the
assembly of the AP-1/PR complex, MPA induced neither
cyclin D1 promoter activation nor cyclin D1 protein ex-
pression (Figure 4D, E).
Transcriptional interaction among AP-1, Stat3, PR and
ErbB-2 at the cyclin D1 promoter
Our earlier work revealed that MPA induces the rapid
phosphorylation of Stat3 and ErbB-2 in breast cancer
cells and the assembly of a transcriptional complex be-
tween Stat3 and ErbB-2 at the Stat3 binding sites (GAS)
in human (position −984) and mouse (positons −971
and −874) cyclin D1 promoters [9]. These sites are close
to the murine −948 TRE (corresponding to the −954
TRE in the human cyclin D1 promoter) (Figure 5A,
upper diagram). Stat3 and AP-1 binding sites are located
near or even juxtaposed in the promoters of a series of
genes and cooperative transcriptional interaction be-
tween Stat3, c-Jun and c-Fos has been found at thepromoters of several Stat3-induced genes [44-46]. We
here explored whether AP-1 and Stat3 interact at the
cyclin D1 promoter. We found that upon 30 minutes of
MPA stimulation of C4HD and T47D cells, Stat3 is
loaded at the region of cyclin D1 proximal promoter
containing TRE and GAS sites, along with c-Jun, c-Fos
and PR (Figure 5A, first and sixth panels). As we re-
cently described [9], MPA also induces the recruitment
of ErbB-2 to this region (Figure 5A, first and sixth
panels). Knockdown of c-Jun or c-Fos expression with
siRNAs in C4HD cells and abolishment of AP-1 tran-
scriptional activity by transfection of TAM-67 or A-Fos
in T47D cells abrogated MPA-induced loading of Stat3
to the cyclin D1 promoter (Figure 5A, second, third, sev-
enth and eighth panels). ErbB-2 was not loaded at the
cyclin D1 promoter in the absence of c-Jun or c-Fos
presence at said promoter by knockdown of their ex-
pressions with siRNAs (Figure 5A, second and third
panels), or when we inhibit c-Jun or c-Fos transcrip-
tional activity by transfecting cells with TAM-67 or
A-Fos (Figure 5A, seventh and eighth panels). As
mentioned above, both strategies abolished Stat3 recruit-
ment to the cyclin D1 promoter (Figure 5A, second, third,
seventh and eighth panels). This result is consistent with
our previous findings demonstrating that ErbB-2 is re-
cruited to the cyclin D1 promoter, which our previous
studies demonstrated that lacks ErbB-2 binding sites
(HAS), via tethering to Stat3 loaded at the GAS sites [9].
Controls (see Additional file 1: Figure 1) show that silen-
cing of c-Jun or c-Fos expressions had no effect on total
levels of Stat3, ErbB-2, and PR protein expressions. To
inhibit ErbB-2 nuclear presence, we transfected cells
with a human ErbB-2 nuclear localization domain mu-
tant (hErbB-2ΔNLS) unable to translocate to the nu-
cleus [31], and which we previously found acts as a
DN inhibitor of endogenous ErbB-2 nuclear transloca-
tion [9]. As we reported [9], Stat3 binds to this region
of the promoter in cells expressing the hErbB-2ΔNLS
but PR is not recruited (Figure 5A, fifth and ninth
panels). We now found that in the absence of ErbB-2
loading, c-Jun and c-Fos are still bound at this region
of cyclin D1 promoter (Figure 5A, fifth and ninth
panels). In addition, sequential ChIPs showed that c-Jun,
c-Fos and ErbB2 co-occupy cyclin D1 promoter after
MPA stimulation (Figure 5B). Our previous re-ChIP
studies demonstrated also the co-recruitment of PR and
ErbB-2 to this region of the cyclin D1 promoter upon
stimulation of T47D cells with MPA [9]. To gain insight
into the function of this cooperative transcriptional inter-
action, we examined the local chromatin architecture.
Since histone acetylation positively correlates with active
gene transcription, we investigated whether co-activators
with chromatin remodeling activity, such as p300 and
CBP, were recruited to the region of the cyclin D1
Figure 4 MPA induces in vivo binding of c-Jun, c-Fos and PR to the cyclin D1 promoter. (A) Protein recruitment to the cyclin D1 promoter
was analyzed by ChIP in cells treated with MPA or pretreated with U0126 when indicated. Immunoprecipitated DNA was amplified by qPCR
using primers flanking the TRE site. The arbitrary qPCR number obtained for each sample was normalized to the input, setting the value of the
untreated sample as 1. Data are expressed as n-fold chromatin enrichment over untreated cells. For b vs. a and c vs. b: P <0.001. (B) Sequential
ChIP chromatins from cells treated with MPA were first immunoprecipitated with c-Jun or c-Fos antibodies and were then re-immunoprecipitated
using a PR antibody. qPCR and data analysis were performed as detailed in A. For b vs. a: P <0.001. Results in A and B are the mean ± SEM from
three independent experiments. IgG was used as a negative control. MPA effects in T47D-Y-C587A-PR cells. (C) Protein recruitment to the cyclin
D1 promoter was studied as described in A. For b vs. a: P <0.001. (D) Cyclin D1 promoter activation was detected as in Figure 3A and data shown
represent the mean of three independent experiments ± SEM. (E) Cyclin D1 expression was studied by WB. This experiment was repeated three
times with similar results. ChIP, chromatin immunoprecipitation; MPA, Medroxyprogesterone acetate; PR, Progesterone receptor; WB, Western blot.
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Figure 5 MPA induces a cooperative transcriptional interaction at the cyclin D1 promoter among AP-1, Stat3, PR and ErbB-2. (A) Cells
were transfected with the indicated siRNAs or expression vectors and were then treated with MPA for 30 minutes. Recruitment of proteins to the
cyclin D1 promoter was analyzed by ChIP. Immunoprecipitated DNA was amplified by qPCR using primers (red arrows) flanking the GAS and TRE
sites indicated in the top panels. Amounts of immunoprecipitated DNA were normalized to inputs and reported relative to the amount obtained
by IgG immunoprecipitation, which was set to one. (B) Sequential ChIP. Chromatins from cells treated with MPA as described in A were first
immunoprecipitated with c-Jun or c-Fos antibodies and were then re-immunoprecipitated using an ErbB-2 antibody. The arbitrary qPCR number
obtained for each sample was normalized to the input, setting the value of the untreated sample as 1. Data are expressed as fold chromatin
enrichment over untreated cells. For b vs. a: P <0.001. (C) Recruitment of CBP and p300, and H3 and H4 acetylation levels (AcH3 and AcH4)
at the sites described in A were studied by ChIP and data were also analyzed as in A. Results in A to C are the mean ± SEM from three independent
experiments. For b vs. a: P <0.001. ChIP, chromatin immunoprecipitation; MPA, Medroxyprogesterone acetate.
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Figure 6 AP-1/Stat3/PR/ErbB-2 transcriptional complex drives progestin-induced breast cancer growth. (A) and (B) Cells transfected as
indicated were treated for 48 (C4HD) or 24 (T47D) h with MPA. Incorporation of [3H]thymidine was measured. Data are presented as the mean ± SD,
P <0.001 for b vs. a and c vs. b. Experiments shown are representative of three. (C) Cyclin D1 protein expression in C4HD cells was analyzed by WB.
(D) AP-1 activity and ErbB-2 nuclear function cooperate to drive in vivo progestin-induced growth. Left, cells (106) from each group were inoculated
s.c. in mice treated with MPA and tumor volume was calculated as described in Methods. Each point represents tumor mean volume ± SEM. Right,
decrease in tumor mass. (E) Tumor growth. aGrowth rates were calculated as the slopes of growth curves. Volume, percentage of growth inhibition
and growth delay in tumors from the experimental groups with respect to tumors from control C4HD-p-Flag cells were calculated at Day 27. # vs. * and c vs. b
for tumor volume and growth rate, P <0.001. d With respect to C4HD-p-Flag cells and f vs. e, P <0.001. g With respect to C4HD-p-Flag cells, P <0.001. (F) ChIP
analysis. DNA-protein complexes were pulled down with the c-Jun antibody or with IgG and DNA was amplified by qPCR using primers indicated in Figure 5.
Results are expressed as in Figure 5A and represent the average of three replicates ± SEM. For b vs. a, P <0.001. Shown is a representative sample of each tumor
type. (G) Tumor lysates were analyzed by WB. C4HD cells growing in absence of MPA are shown as control: Shown are two representative samples of mice
injected with the different experimental groups. See also Additional file 1: Figure 3. ChIP, chromatin immunoprecipitation; MPA, Medroxyprogesterone acetate;
WB, Western blot.
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http://breast-cancer-research.com/content/15/6/R118promoter containing the TRE and GAS sites. As shown in
Figure 5C (first and fifth panels), CBP and p300 were
loaded in this region by MPA treatment of C4HD and
T47D cells. Consistently, histone H3 and H4 acetylation
was significantly enhanced by MPA (Figure 5C, first and
fifth panels). Abrogation of the recruitment of AP-1 and
Stat3 to their respective binding sites and consequent
blockade of cofactors (PR and ErbB-2) binding (Figure 5C
second to fourth, sixth and seventh panels) resulted in
neither CBP/p300 recruitment nor modification of histone
acetylation levels. Similarly, in spite of Stat3 and AP-1
binding to their response elements in cells transfected
with hErbB-2ΔNLS, in the absence of ErbB-2 and PR
loading no markers of chromatin activation were found
(Figure 5C, eighth panel). Our findings for the first time
reveal the bidirectional nature of the transcriptional inter-
action between AP-1 and Stat3 and their interacting
cofactors, PR and ErbB-2, which function in the manner
of an enhanceosome, that is, an array of transcription
factors (AP-1 and Stat3), whose response elements are
clustered in the DNA, plus their interacting cofactors
(PR and ErbB-2) and co-activators (P300 and CBP)
that function cooperatively, in this case to induce cyc-
lin D1 promoter activation upon progestin stimulation
of breast cancer cells.
A multimeric AP-1/Stat3/PR/ErbB-2 transcriptional complex
drives progestin-induced in vitro and in vivo breast cancer
growth
To explore the involvement of AP-1 in progestin-induced
breast cancer growth, we transiently transfected C4HD
cells with a p-Flag vector (C4HD-p-Flag) as control, with
TAM-67 (C4HD-TAM-67) or A-Fos (C4HD-A-Fos),
and also co-transfected them with TAM-67 and A-Fos
(C4HD-TAM-67/A-Fos). Our studies using [3H]-thymidine
incorporation as a measure of DNA synthesis, showed that
C4HD-TAM-67 and C4HD-A-Fos cells were unresponsive
to MPA proliferative effects (Figure 6A). Importantly, we
previously demonstrated that [3H]-thymidine uptake corre-
lates with the number of cells/well in the C4HD model [2],
a direct measure of cell proliferation. Consistent with c-Jun
and c-Fos function as a heterodimer to assemble the AP-1
transcription factor [15] and with our present findings
revealing that both are directly involved in MPA-induced
AP-1 transcriptional activation (Figure 3), we found com-
parable levels of inhibition of MPA-induced growth in
C4HD-TAM-67/A-Fos cells to those observed in C4HD-
TAM-67 and C4HD-A-Fos cells. Similar results were
found in T47D cells (Figure 6B). These findings reveal
that AP-1 activation is mandatory for progestin-driven
breast cancer cell growth. On the other hand, we re-
cently found that transfection of C4HD cells with the
hErbB-2ΔNLS (C4HD-hErbB-2ΔNLS) renders them un-
responsive to in vitro and in vivo growth stimulated byprogestin [9]. Importantly, previous findings and our own
work demonstrated that hErbB-2ΔNLS retains its intrinsic
tyrosine kinase activity as well as the capacity to activate
classical ErbB-2 cascades, and does not affect endogenous
ErbB-2 signaling [9,31]. In light of our present findings
showing the assembly of an AP-1/Stat3/PR/ErbB-2 enhan-
ceosome at the cyclin D1 promoter, we explored the effects
in proliferation of the simultaneous blockade of ErbB-2 nu-
clear localization and AP-1 activation. Co-transfection with
either TAM-67 or A-Fos and hErbB-2ΔNLS into C4HD
cells (C4HD-TAM-67/hErbB-2ΔNLS and C4HD-A-Fos/
hErbB-2ΔNLS, respectively) resulted in levels of growth in-
hibition comparable to those observed in C4HD-TAM-67
and C4HD-A-Fos cells (Figure 6A). No significant effects
on basal cell proliferation were observed by transfection
with any of the expression plasmids or the combination of
them (Figure 6A, B) In accordance with the similar effects
on growth inhibition observed in our different experimen-
tal approaches designed to abolish the assembly of the AP-
1/Stat3/PR/ErbB-2 enhanceosome, comparable levels of
blockade of cyclin D1 expression were found in all six cell
types (Figure 6C). Proliferation in C4HD cells was also
evaluated by propidium iodide staining and flow cytometry
analysis with similar results (Additional file 1: Figure 3A).
We then developed a preclinical model to address the ef-
fect of the blockade of AP-1 activation and of the simultan-
eous abrogation of AP-1 activity and ErbB-2 nuclear
translocation in in vivo growth using the C4HD mouse
mammary tumor model. Here, 106 C4HD-p-Flag, C4HD-
TAM-67, C4HD-A-Fos, C4HD-hErbB-2ΔNLS and C4HD-
TAM-67/hErbB-2ΔNLS cells were inoculated s.c. into mice
treated with MPA. All mice (n = 6) injected with control
C4HD-p-Flag cells developed tumors which became palp-
able after seven days of inoculation. Only four out of six
mice injected with C4HD-TAM-67, C4HD-A-Fos and
C4HD-hErbB-2ΔNLS cells developed tumors with a delay
of four days in tumor latency compared with tumors from
C4HD-p-Flag cells. In mice injected with C4HD-TAM-67/
hErbB-2ΔNLS cells, three out of six developed tumors
with a delay of seven days in latency as compared to
the control group. Tumor mean volumes and growth
rates (Figure 6D-E) from all experimental groups were
significantly lower than those from the controls. Not-
ably, the mean volumes and growth rates of tumors
from C4HD-TAM-67/hErbB-2ΔNLS cells were also
significantly lower than those of tumors from C4HD-
TAM-67, C4HD-A-Fos and C4HD-hErbB-2ΔNLS cells
(Figure 6E). Here we are describing a representative
experiment of a total of two. Tumors were excised at
Day 27 and the results are summarized in Figure 6E
and Additional file 1: Figure 3B. It is of note that the
C4HD tumor model is absolutely dependent on the
administration of MPA for growing in vivo [47-49],
therefore, no tumors developed in mice injected with
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tion after 27 days of inoculation. Next, we examined
the AP-1 functional state in tumor samples in order to
provide a direct mechanistic link between AP-1 tran-
scriptional activity and MPA-induced in vivo growth.
ChIP analysis showed c-Jun recruitment to the region
of cyclin D1 promoter containing TRE and GAS sites
in C4HD-p-Flag tumors (Figure 6F). On the contrary,
we did not detect c-Jun loading in C4HD-TAM-67,
C4HD-A-Fos or C4HD-TAM-67/hErbB-2ΔNLS tu-
mors (Figure 6F). Low levels of c-Jun binding were
found in C4HD-hErbB-2ΔNLS tumors (Figure 6F),
consistent with our studies in cells, which, however,
showed no markers of chromatin activation at this re-
gion (Figure 5A, C). In accordance with our demon-
stration that the AP-1/Stat3/PR/ErbB-2 complex assembled
at the cylin D1 promoter upon MPA stimulation modulates
cyclin D1 expression, significantly lower levels of cyclin D1
were found in tumors from all experimental groups as com-
pared with control samples (Figure 6G). These results pro-
vide the first direct link among AP-1 and Stat3 cooperative
transcriptional activity, cyclin D1 expression, and in vivo
progestin-induced breast cancer growth. In line with previ-
ous findings revealing that TAM-67 and A-Fos act at the
level of AP-1 transcriptional activity [29,30], we found simi-
lar levels of c-Jun phosphorylation in tumors from all ex-
perimental groups (Figure 6G). Moreover, and as a further
demonstration that indeed the transcriptional effects of
Stat3, PR and ErbB-2 govern cyclin D1 expression and
in vivo progestin-induced breast cancer growth, comparable
Stat3 phosphorylation levels and ErbB-2 phosphorylation at
one of the major sites of autophosphorylation, Tyr 1272, as
well as at Tyr 877, a site other than the autophosphorylation
ones, which we already revealed is rapidly phosphorylated
by progestins [9], were detected in all tumors (Figure 6G).
Also, p42/p44 MAPKs, downstream effectors of PR and
ErbB-2, were comparably activated in all experimental
groups (Figure 6G). Similar levels of PR were found in all
tumor samples, indicating that the antiproliferative effects of
the blockade of AP-1 activation, and consequently of the as-
sembly of the AP-1/Stat3/PR/ErbB-2 transcriptional com-
plex, are not due to regulation of PR expression levels, but
to the blockade of the assembly of PR nonclassical transcrip-
tional complexes (Figure 6G).
Association of phosphorylated c-Jun and PR nuclear
colocalization with risk factors and clinical outcome in
breast cancer
To explore the clinical significance of PR and AP-1 nu-
clear interaction, we conducted a retrospective study in a
cohort of 99 PR + primary invasive breast carcinomas. The
clinical and pathological characteristics of these specimens
are shown (Additional file 1: Table S2). We studied the
nuclear colocalization of PR and phosphorylated c-Jun(p-c-Jun) in TMAs from our cohort by immunofluor-
escence (IF) and confocal microscopy. PR expression
in the TMAs was explored by IF using PgR 1294 anti-
body and its levels were scored in accordance with the
Allred score [41]. We analyzed p-c-Jun expression by
IF using the Ser 63/73 antibody, as in our experimental
models. Nuclear p-c-Jun levels detected by IF were also
scored with the Allred system, considering both the
percentage of positive cells and staining intensity, on a
scale of 0 to 8. As previously described [50], substan-
tial levels of nuclear p-c-Jun by IF staining were found
in our cohort, where all tumors displayed scores between
5 and 8. Representative samples are shown in Figure 7A.
We then established a score for nuclear colocalization of
PR and p-c-Jun in which 0 represents faint or no colocali-
zation in less than 10% of cells, 1+ weak colocalization in
10 to 25%, 2+ moderate colocalization in 26 to 50%, and
3+ strong colocalization in >50% of cells (Figure 7A).
Scores of 2+ and 3+ were considered positive for colo-
calization. We found that 81 tumors (82%, 95% CI =
73% to 89%) showed nuclear colocalization. Next, we
evaluated the relationship between p-c-Jun and PR
colocalization and the clinicopathological characteris-
tics of our cohort, and found that it was significantly
associated with the absence of nodal metastasis (Table 1).
Kaplan-Meier survival analysis revealed that colocalization
correlated with better OS (Figure 7B). Finally, multivariate
analysis revealed that p-c-Jun/PR colocalization is a
significant independent predictor of better survival (HR:
0.32, 95% CI: 0.12 to 0.85, P = 0.022). This was an unex-
pected finding given our results indicating that the assem-
bly of the PR/AP-1 complex drives progestin-stimulated
breast cancer growth. To reconcile these discrepancies,
and based on previous findings showing that PR activation
of signaling cascades and proliferative effects in breast
cancer may occur via PR crosstalk with ERα [3,51,52], we
reasoned that the assembly of the PR/AP-1 complex might
be involved in the response to therapy, which currently
targets ERα. To test our hypothesis, we explored the OS
in the subgroup of patients ER+/PR + (n = 85) that
received tamoxifen (Tam), a selective ER modulator
(SERM), in the adjuvant setting. We found that among
patients that received Tam, those whose tumors displayed
nuclear colocalization of p-c-Jun and PR showed a signifi-
cantly higher OS than patients whose tumors lacked
colocalization (Figure 7B). Comparable mean and range
of p-c-Jun and PR scores were found in both sets
(Additional file 1: Tables S3 A, B). Membrane ErbB-2
overexpression is associated with poor clinical outcome in
ER+/PR + patients treated with Tam [10,53-56]. Our find-
ings revealed that ErbB-2 overexpression was inversely
associated with p-c-Jun and PR colocalization in our
Tam-treated cohort, which further highlights the role
of p-c-Jun/PR colocalization as a biomarker of response to
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Figure 7 PR and AP-1 interaction clinical significance. PR and p-c-Jun colocalization in tumor samples. (A) Nuclear p-c-Jun and PR levels were
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tionship between Tam effects and the assembly of the PR/
AP-1 complex, we went back to our experimental models.
We treated cells with Tam at a concentration (1 μM) in
which it acts as antagonist on ERα actions, and which,
therefore, mimics the expected response to Tam
in patients [3,57-60]. We found that Tam abrogated
progestin-induced growth of T47D cells (Figure 8A, left
panel) and also inhibited MPA-induced c-Jun phosphoryl-
ation and AP-1-mediated transcriptional activation of thecyclin D1 promoter (Figure 8A, middle and right panels,
respectively). No effects on basal cell growth, c-Jun phos-
phorylation or AP-1 activation were detected by treatment
with Tam alone (Figure 8A). Consistent with our findings
that c-Jun phosphorylation is mandatory for it to load at
the cyclin D1 promoter (Figure 4), we found that Tam
inhibited c-Jun binding to said region (Figure 8B). As
we showed above (Figures 4 and 5), in the absence of
c-Jun binding, PR is not recruited to the promoter
(Figure 8B). To further assess Tam’s role on progestin-
Table 1 Univariate analysis of clinical and pathological characteristics of 99 PR + breast cancer patients in relation to
p-c-Jun and PR colocalization positivity using Odds ratio model
p-c-Jun and PR colocalization
Variable Characteristics (−) N = 128 (+) N = 81 OR (Odds ratio) 95% CI (Confidence interval) P-value
Clinicopathological data
Age (Y) <50 6 33 0.73 0.2 to 2.3 0.56a
>50 12 48
Tumor size <20 mm 1 15 0.25 0.005 to 1.94 0.29b
>20 mm 17 66
Lymph node metastasis Negative 3 38 0.22 0.04 to 0.9 0.019b
Positive 15 43
Distant metastasis M0 17 76 1.1 0.1 to 56 1b
M1 1 5
Clinical stage I + II 11 50 0.97 0.3 to 3.3 0.96a
III + IV 7 31
Tumor grade Well to moderately differentiatedc 13 68 0.49 0.13 to 2.1 0.3b
Poorly differentiatedc 5 13
Estrogen receptor (ER) Negative 1 6 0.74 0.01 to 6.7 1b
Positive 17 75
aχ2 Test.
bFisher’s exact test.
cWell to moderately differentiated: tumor grade 1 + 2; poorly differentiated: tumor grade 3.
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cer growth, we used BT474 breast cancer cells which
express ERα and PR, overexpress ErbB-2, and are fully
resistant to Tam antiproliferative effects [61]. In addition,
we used a BT474-HR clone which we selected for its re-
sistance to the effects of the ErbB-2 antibody trastuzumab,
employed for treatment of ErbB-2-positive breast cancer
(Additional file 1: Figure 4A) and the BT474-HR6 clone
selected for its resistance to trastuzumab in a previous
work [27]. Estrogen-driven growth was found to be inhib-
ited by Tam in BT474 clones resistant to trastuzumab
[61], suggesting a reactivation of ERα dominant role in the
proliferation of these cells. As described for 17-β estradiol
(E2) ([61] and Figure 8C), we found that Tam abrogated
MPA-induced proliferation of BT474-HR cells (Figure 8C)
but it does not affect their basal proliferation (Figure 8C).
Similarly, MPA-driven growth was inhibited by Tam in
BT474-HR6 cells (Additional file 1: Figure 4B). MPA also
induced growth of BT474 parental cells which remained
unaffected by Tam (Figure 8D). As control of the classic-
ally defined Tam-resistant behavior of BT474 cells [61],
we are showing that Tam does not inhibit their E2-
induced growth and, that when added alone, Tam shows
agonistic actions (Figure 8D). As previously reported,
similar levels of ErbB-2 and ERα were found in BT474
cells and in HR and HR6 clones (Figure 8E) [27,61,62]. On
the contrary, we found lower levels of PR expression in
HR and HR6 clones as compared to parental BT474
cells, which has previously been observed in BT474and UACC812 breast cancer cells and their respective
trastuzumab-resistant clones [62]. PR activation of the
c-Src/p42/p44MAPKs pathway occurs in ERα-dependent
and -independent manners [3-5,51]. Here, we found that
MPA induced a rapid increase in the phosphorylation of
c-Src and p42/p44MAPKs in BT474-HR cells, which was
abrogated by Tam (Figure 8F). No effects were observed
by treatment with Tam alone (Figure 8F). MPA also in-
duced phosphorylation of c-Jun in these cells, which was
abolished by preventing c-Src/p42/p44MAPKs activation
when Tam was added along with MPA (Figure 8F). Tam
alone had no effect on c-Jun phosphorylation (Figure 8F).
Most interesting are our results with BT474 parental cells.
High levels of basal c-Src, p42/p44MAPKs and c-Jun
phosphorylation were found in these cells which were
enhanced by MPA (Figure 8G). Tam increased MPA-
induced phosphorylation of all these proteins (Figure 8G).
Also, Tam exerted a clear agonist action in BT474 cells,
stimulating c-Src, p42/p44MAPKs and c-Jun activation
(Figure 8G). Inhibition of p42/p44MAPKs activity with
UO126 in BT474-HR and BT474 cells also resulted in
complete blockade of MPA-induced c-Jun phosphoryl-
ation (Additional file 1: Figure 5), demonstrating the direct
involvement of p42/p44MAPKs in MPA effects. We then
explored the involvement of the nuclear interaction be-
tween c-Jun and PR in the response to Tam. MPA induced
the recruitment of c-Jun and PR to the cyclin D1 pro-
moter in BT474-HR cells, which was abrogated by Tam
(Figure 8H). No loading of said proteins was observed by
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Figure 8 PR and AP-1 interaction involvement in endocrine therapy response. (A) Proliferation , c-Jun phosphorylation and cyclin D1 promoter
activation were studied as described in Figures 1, 3 and 6. (B) c-Jun and PR recruitment to the cyclin D1promoter was analyzed by ChIP as in Figure 5.
Data are expressed as n-fold chromatin enrichment over untreated cells. For b vs. a and c vs. b: P <0.001. (C) to (J) Tam effects in sensitive and resistant
cells. (C) and (D) Cell variants were treated as shown and proliferation was studied as in Figure 6. (E) Protein levels were analyzed by WB. Signal
intensities of PR-A and PR-B bands were analyzed by densitometry and normalized to β-tubulin. Densitometric analysis of PR-A and PR-B expression
levels in HR and HR6 clones, relative to those in BT474 cells (set to 1), are shown in the right panel. (F) and (G) WB in BT474-HR (F) and BT474
cells (G) were performed with the indicated phospho-antibodies and filters were re-probed with the respective total antibody. Signal intensities of
phospho-proteins were normalized to total protein bands. Significance of MPA and Tam effects on the regulation of protein phosphorylation was analyzed as
described in Methods (P <0.001). (H) and (I) c-Jun, PR, and ER α recruitment to the cyclin D1 promoter was studied by ChIP. We set as 1 the value of the
untreated sample for BT474-HR cells (H) and of the IgG for BT474 (I). For b vs. a and c vs. b: P <0.001. (J) Tam effects on cyclin D1 protein expression. WBs were
performed as in Figure 3 using β tubulin as loading control. Experiments in A to J were repeated five times with similar results. See Additional file 1: Figures 4,
5 and 6. ChIP, chromatin immunoprecipitation; MPA, Medroxyprogesterone acetate; PR, Progesterone receptor; Tam, Tamoxifen WB, Western blot.
Díaz Flaqué et al. Breast Cancer Research 2013, 15:R118 Page 18 of 24
http://breast-cancer-research.com/content/15/6/R118stimulation with Tam alone (Figure 8H). Differential nu-
clear interaction of ERα with co-activators and co-
repressors plays a key role in Tam response [53,63-65].
Therefore, we explored whether ERα may also be re-
cruited along with c-Jun and PR to the cyclin D1 pro-
moter. We found that MPA induced ERα recruitment to
said promoter region, which was abrogated by Tam
(Figure 8H). Tam alone did not stimulate ERα binding
(Figure 8H). Since our database [66] and literature
searches did not identify canonical or half estrogen re-
sponse elements (EREs) in the cyclin D1 promoter tar-
get region under study, our results indicate that ERα
acts as an AP-1 cofactor, along with PR. Our findings
in BT474 cells revealed high levels of basal c-Jun re-
cruitment to the cyclin D1 promoter, which were in-
creased by MPA (Figure 8I). Tam also significantly
increased MPA-induced c-Jun loading at said promoter
(Figure 8I), and when added alone, it stimulated c-Jun
binding. In addition, MPA and Tam stimulated PR recruit-
ment to the cyclin D1 promoter (Figure 8I), and Tam po-
tentiated MPA capacity to recruit PR (Figure 8I). Neither
MPA nor Tam nor their combination induced ERα load-
ing at this region of the promoter. Control of c-Fos
co-recruitment with c-Jun and PR to the cyclin D1
promoter to assemble the AP-1/PR complex in BT474-HR
cells is shown in Additional file 1: Figure 6. Our findings
also demonstrated that MPA-induced cyclin D1 protein ex-
pression in BT474-HR cells was abolished by Tam, which
on the other hand, caused no effect on cyclin D1 levels
when acting alone (Figure 8J). In contrast, Tam enhanced
cyclin D1 expression induced by MPA, and also increased
cyclin D1 levels when added alone in BT474 cells
(Figure 8J). We performed IF staining in BT474-HR and
BT474 cells to compare the images on the subcellular
localization of PR and p-c-Jun with our findings in the
clinic. BT474 cells, growing in the absence of MPA,
displayed high levels of nuclear PR (7+) and p-c-Jun
(8+) (Figure 9). However, they would classify as 1+
in our clinical nuclear p-c-Jun/PR colocalization
score, mimicking a tumor negative for colocalization(Figure 9). MPA and Tam and their combination
stimulate nuclear colocalization of both proteins
(Figure 9), with scores of 2+ or 3+. BT474-HR cells with-
out MPA treatment show scores of 5+ to 6+ for nuclear
PR expression, 8+ for p-c-Jun and no protein colocaliza-
tion (Figure 9). In contrast with the almost exclusive nu-
clear localization of PR in BT474 cells, we found the
presence of cytoplasmic PR in BT474-HR cells (Figure 9).
The image is strikingly different upon MPA stimulation,
which results in significant nuclear migration of PR (7+)
and colocalization with p-c-Jun (3+) (Figure 9). Tam had
no effects on nuclear p-c-Jun and PR colocalization and
abrogated MPA effects (Figure 9). These findings revea-
led that IF images of BT474 cells in the absence of
MPA stimulation and of BT474-HR cells treated with
MPA, mimic the respective portraits of Tam-resistant
and -sensitive tumors, which we revealed using PR and
c-Jun colocalization as biomarker.
Discussion
Our findings demonstrate that coordinated PR rapid and
nonclassical transcriptional effects govern breast cancer
growth and offer novel mechanistic insight into one of
the major challenges in the clinical management of
breast cancer: endocrine therapy resistance.
We showed that MPA induces phosphorylation of c-Jun
and c-Fos and AP-1 transcriptional activation in breast
tumor cells via PR-activated p42/p44 MAPKs. MPA ef-
fects were mediated by PR-B but not by PR-A, which con-
tributes to explain the fact that in breast cancer the
majority of the target genes are exclusively regulated
through one isoform or the other, principally through PR-
B [67]. Progestin rapidly activates p42/p44 MAPKs in
breast cancer which mediate multiple aspects of PR
function [1,8]. We revealed that the capacity of progestin-
activated p42/p44 MAPKs to phosphorylate c-Jun and c-Fos
is an integration point of PR rapid and nonclassical tran-
scriptional mechanisms.
Cyclin D1 is a paradigmatic gene induced by progestin in
breast cancer [8,9,11]. A link among PR, AP-1 and cyclin
Figure 9 PR and p-c-Jun colocalization in BT474 cell variants. Nuclear p-c-Jun and PR levels were evaluated by IF and scored as described in
Results and shown in Figure 7A. Protein colocalization was visualized as nuclear yellow dots. Nuclei were stained with DAPI (blue). IF, Immunofluorescence;
PR, Progesterone receptor.
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stimulated breast cancer cells, PR and c-Jun are recruited
to an estrogen-sensitive region at the proximal cyclin D1
promoter which contains the AP-1 site [68]. We previously
found that progestin induces Cyclin D1 expression via the
assembly of a transcriptional complex between Stat3 andErbB-2 at the GAS sites of the proximal cyclin D1 pro-
moter [9]. Our present findings revealed a new level of
complexity in this mechanism showing that AP-1 is also
loaded at the TRE located in close proximity to the GAS
site in said promoter, and that PR is simultaneously re-
cruited. Cooperative transcriptional interaction between
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http://breast-cancer-research.com/content/15/6/R118Stat3, c-Jun and c-Fos has been reported at the promoters
of several Stat3-induced genes, including some involved in
carcinogenesis and metastasis [44-46]. Here, we show the
assembly of a complex of TFs (Stat3 and AP-1) and their
interacting cofactors (PR and ErbB-2) (Figure 10 illustrates
our model) which functions cooperatively to induce cyclin
D1 promoter activation and breast cancer growth.
Expression of the different AP-1 members and increased
AP-1 transcriptional activity were found in breast cancer
where AP-1 participates in the regulation of growth, inva-
sion and resistance to Tam [20-22,50,69-71]. Our findings
demonstrate that inhibition of AP-1 activity blocks
in vitro and in vivo progestin-induced breast tumor
growth. Our discovery at the cyclin D1 promoter of
the AP-1/Stat3/PR/ErbB-2 enhanceosome, may explain
the similar levels of in vitro growth inhibition we found by
abrogation of AP-1 activity, preventing nuclear ErbB-2
presence or the combination of both strategies. The out-
put of all three strategies on cyclin D1 expression is inErbB
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erative rates among our preclinical models, suggesting
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ingly, in the mentioned study nuclear p-c-Jun in ER +
tumors correlated with lack of endocrine response [50],
can be explained by our combined experimental and
clinical data. High levels of nuclear staining for p-c-Jun in
BT474 cells in the absence of progestin stimulation,
reflect c-Jun activation by the c-Src/p42/p44MAPKs
cascade, which is also active under basal conditions.
BT474 cells express ErbB ligands, and ErbB tyrosine
kinase inhibitors block p42/p44 MAPKs activation in
these cells [27,62]. Therefore, we speculate that in BT474
cells, c-Jun is constitutively phosphorylated by endogen-
ous ErbB ligands via p42/p44 MAPKs. On the other hand,
previous findings, including our own, showed that p42/
p44 MAPKs, activated by ErbB ligands, induce PR phos-
phorylation and nuclear translocation [72,73], which may
explain the extensive PR nuclear presence found when
there is no progestin stimulation of BT474 cells. However,
under basal conditions, these cells show no nuclear c-Jun/
PR colocalization, and in spite of c-Jun loading at the
cyclin D1 promoter, PR is not recruited as a cofactor. Our
findings on MPA treatment of BT474 cells are consistent
with a model of Tam resistance in the clinic where, firstly,
exposure to an endogenous progestational milieu, mim-
icked in our study with MPA, of ER+/PR + tumors dis-
playing at diagnosis p-c-Jun nuclear presence but lacking
p-c-Jun/PR colocalization, will enhance p-c-Jun levels and
induce the assembly of an AP-1/PR complex and tumor
proliferation. Secondly, such as we found in BT474 cells,
in this tumor type Tam will enhance high basal levels of
activated c-Src/p42/p44MAPKs, consequently increasing
c-Jun phosphorylation, AP-1/PR complex formation, and
tumor growth. Thirdly, when present together, Tam and
progesterone will exert cooperative effects on the assembly
of the growth-promoting AP-1/PR complex. ERα genomic
actions appear not to be involved in progestin nor Tam
effects, as we found no recruitment of ERα to the AP-1/PR
transcriptional complex in BT474 cells. This is consistent
with previous findings showing that ERα is located mostly
at the cytoplasm in BT474 cells, and in several breast
cancer cells overexpressing ErbB-2 [61,74]. This ectopic
ERα location would therefore prevent Tam antagonistic ef-
fects on ERα genomic actions. Ours is the first demonstra-
tion that a mechanism underlying Tam resistance is
the ability of Tam to assemble an AP-1/PR transcriptional
complex at a region of the cyclin D1 proximal promoter
lacking canonical or half PREs or EREs, via the cooption of
ERα signaling function, independently of ERα recruitment
to said complex.
Anti-estrogens and progestin interaction leading to
breast cancer growth has been revealed. Progestin was
found to induce cyclin D1 expression and proliferation
in anti-estrogen-arrested breast cancer cells [75]. Differ-
ences in ErbB-2 or ERα levels cannot account fordifferential Tam responses since we found similar levels
of both proteins in BT474 cells, HR and HR6 clones, as
already reported [27,61,62]. Our results on the lower PR
levels in BT474-HR and HR6 cells, as compared to paren-
tal BT474 cells are consistent with previous findings [62].
PR is still clearly expressed in our Tam-responsive cells,
with a score that would be considered a PR-positive tumor,
which suggests that control of PR levels would result in
substantial PR involvement in the formation of transcrip-
tional complexes via its interaction with ERα, which are
susceptible to being inhibited by Tam.
Our results in BT474-HR cells revealed that the hall-
mark of PR role in Tam-sensitive cells is the requirement
for PR to crosstalk with unliganded ERα to activate the
Src/p42/p44MAPKs cascade leading to c-Jun phosphor-
ylation and AP-1/PR complex formation. We also found
that progestin recruits unliganded ERα as a cofactor to
the AP-1/PR complex. Blockade of ERα function with
Tam therefore inhibits coordinated PR rapid and tran-
scriptional effects leading to tumor growth. A puzzling
finding of our work has been that while staining of
BT474 cells in the absence of MPA stimulation mimics
the portrait of a Tam-resistant tumor we revealed by
using PR and c-Jun colocalization as biomarker, staining
of BT474-HR cells in the presence of MPA resembles a
Tam-sensitive tumor. It is tempting to hypothesize that
BT474 cells represent tumors whose proliferation is
mostly dependent on growth factors, and that therefore
at the time of diagnosis, they will display a hormone-
independent profile, regarding the p-c-Jun/PR marker.
On the contrary, BT474-HR cells mimic tumors in
which the hormonal stimulus is still key in driving
growth. Therefore, when detected, this tumor type will
show a pattern of p-c-Jun/PR colocalization associated
with hormonal control of proliferation.
Studies of differential gene expression between endocrine
resistant and responsive breast tumors before and after
treatment identified genes that predict response and re-
vealed agonist actions of Tam [76]. Notably, cyclin D1,
which we here found is modulated via an AP-1/PR inter-
action which Tam potentiates in resistant cells, was among
the genes whose expression was dramatically increased
after treatment only in resistant tumors [76]. Cyclin D1
overexpression in breast cancer is associated with both
good outcome [77] and Tam resistance [78]. Our findings
revealed a mechanism which links AP-1 activation and in-
duction of cyclin D1 expression to Tam resistance.
Conclusions
Although progestin induces breast cancer growth, PR
presence in breast tumors is an independent marker of
good prognosis [79], and PR loss in ER + tumors is asso-
ciated with reduced response to endocrine therapies
[79]. We here provided novel insight into the paradox of
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as a major driver of mammary tumor growth, its role as
a marker of good prognosis may be explained by our
demonstration that in breast cancer cells sensitive to
endocrine therapy with Tam, PR must interact with
unliganded ERα to exert its rapid and genomic effects
leading to the assembly of transcriptional complexes
which govern breast cancer growth. Therefore, blockade
of ERα function would also inhibit coordinated PR rapid
and transcriptional effects, and consequently, PR-mediated
proliferation. Our findings have also highlighted the neces-
sity of developing new biomarkers of response to endo-
crine therapy based on the assessment of surrogates of PR
function, such as the nuclear colocalization of PR with p-c-
Jun, which our combined studies in the clinic and in cell
models identified as a predictor of Tam response. Our
mechanistic studies suggest that nuclear presence of PR
and p-c-Jun, in the absence of said proteins colocalization,
is a hallmark of hormone-independent activation of c-Jun
and PR and stimulation of tumor growth, unlikely to res-
pond to ER-targeted therapies.Additional file
Additional file 1: Supplemental data. File contains all supplemental
figures, tables and methods cited in this article.
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